Terms: = Thyroid cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
121 results:
1. Influence of different pH milieu on the structure and function of human Aurora kinase B protein (AURK-B): Amalgamation of both spectroscopic and computational approach.
Gupta D; Kumari R; Kumar M; Singh M; Rawat S; Ethayathulla AS; Kaur P
Spectrochim Acta A Mol Biomol Spectrosc; 2024 May; 312():124047. PubMed ID: 38394881
[TBL] [Abstract] [Full Text] [Related]
2. Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata.
Zheng XY; Ma YP; Zhang B; Chen YX; Tang L; Tai XH; Cao JH
Front Endocrinol (Lausanne); 2023; 14():1309620. PubMed ID: 38292771
[TBL] [Abstract] [Full Text] [Related]
3. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
Trevisani V; Iughetti L; Lucaccioni L; Predieri B
Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
[TBL] [Abstract] [Full Text] [Related]
4. Toxicities associated with immune checkpoint inhibitors: a systematic study.
Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
[TBL] [Abstract] [Full Text] [Related]
5. A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.
Lv W; He X; Wang Y; Zhao C; Dong M; Wu Y; Zhang Q
Sci Rep; 2023 Apr; 13(1):6403. PubMed ID: 37076508
[TBL] [Abstract] [Full Text] [Related]
6. Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer.
Roy AM; George S
Immunotherapy; 2023 Apr; 15(6):397-400. PubMed ID: 36861344
[TBL] [Abstract] [Full Text] [Related]
7. A case report of anterior mediastinal signet ring cell carcinoma.
Liu S; Zhao A; Mao M
Medicine (Baltimore); 2022 Dec; 101(48):e32202. PubMed ID: 36482538
[TBL] [Abstract] [Full Text] [Related]
8. Oral lichenoid lesion simultaneously associated with Castleman's disease and papillary thyroid carcinoma: a rare case report.
Zhou J; Zhou R; Tan P; Cheng B; Ma L; Wu T
BMC Oral Health; 2022 Dec; 22(1):572. PubMed ID: 36476460
[TBL] [Abstract] [Full Text] [Related]
9. thyroid-related adverse events induced by immune checkpoint inhibitors.
Chera A; Stancu AL; Bucur O
Front Endocrinol (Lausanne); 2022; 13():1010279. PubMed ID: 36204105
[TBL] [Abstract] [Full Text] [Related]
10. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer.
Lv W; Tan Y; Zhou X; Zhang Q; Zhang J; Wu Y
Front Immunol; 2022; 13():989928. PubMed ID: 36189319
[TBL] [Abstract] [Full Text] [Related]
11. What is the status of immunotherapy in thyroid neoplasms?
Garcia-Alvarez A; Hernando J; Carmona-Alonso A; Capdevila J
Front Endocrinol (Lausanne); 2022; 13():929091. PubMed ID: 35992118
[TBL] [Abstract] [Full Text] [Related]
12. Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in cancer.
Ferreira MN; Rao M; Kamal AH; Shariff A
J Palliat Med; 2022 Nov; 25(11):1715-1720. PubMed ID: 35696238
[TBL] [Abstract] [Full Text] [Related]
13. Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer.
Lin J; Zhao A; Fu D
Sci Rep; 2022 Jun; 12(1):9311. PubMed ID: 35665772
[TBL] [Abstract] [Full Text] [Related]
14. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive thyroid cancer.
Ragusa F; Ferrari SM; Elia G; Paparo SR; Balestri E; Botrini C; Patrizio A; Mazzi V; Guglielmi G; Foddis R; Spinelli C; Ulisse S; Antonelli A; Fallahi P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628540
[TBL] [Abstract] [Full Text] [Related]
15. Measurement of neutron equivalent dose in the thyroid, chiasma, and lens for patients undergoing pelvic radiotherapy: A phantom study.
Shojaei M; Rashedi S; Chakoli AN; Karimi AH; Geraily G
Appl Radiat Isot; 2022 Jun; 184():110188. PubMed ID: 35358808
[TBL] [Abstract] [Full Text] [Related]
16. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
[TBL] [Abstract] [Full Text] [Related]
17. Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy.
Orlova R; Zhukova N; Malkova A; Shoenfeld Y
Cancer Treat Res Commun; 2022; 31():100529. PubMed ID: 35131574
[TBL] [Abstract] [Full Text] [Related]
18. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract] [Full Text] [Related]
19. Increased Risk of thyroid Dysfunction by PD-1 and ctla-4 Blockade in Patients Without thyroid Autoantibodies at Baseline.
Iwama S; Kobayashi T; Yasuda Y; Okuji T; Ito M; Ando M; Zhou X; Yamagami A; Onoue T; Kawaguchi Y; Miyata T; Sugiyama M; Takagi H; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Wakahara K; Yokota K; Kato M; Nishio N; Tanaka C; Miyata K; Ogura A; Ito T; Sawada T; Shimokata T; Niimi K; Ohka F; Ishigami M; Gotoh M; Hashimoto N; Saito R; Kiyoi H; Kajiyama H; Ando Y; Hibi H; Sone M; Akiyama M; Kodera Y; Arima H
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1620-e1630. PubMed ID: 34791304
[TBL] [Abstract] [Full Text] [Related]
20. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with ctla4-related hypophysitis.
Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
[TBL] [Abstract] [Full Text] [Related]
[Next]
